1.Role of radiotherapy in extensive-stage small cell lung cancer after durvalumab-based immunochemotherapy: A retrospective study.
Lingjuan CHEN ; Yi KONG ; Fan TONG ; Ruiguang ZHANG ; Peng DING ; Sheng ZHANG ; Ye WANG ; Rui ZHOU ; Xingxiang PU ; Bolin CHEN ; Fei LIANG ; Qiaoyun TAN ; Yu XU ; Lin WU ; Xiaorong DONG
Chinese Medical Journal 2025;138(17):2130-2138
BACKGROUND:
The purpose of this study was to evaluate the safety and efficacy of subsequent radiotherapy (RT) following first-line treatment with durvalumab plus chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC).
METHODS:
A total of 122 patients with ES-SCLC from three hospitals during July 2019 to December 2021 were retrospectively analyzed. Inverse probability of treatment weighting (IPTW) analysis was performed to address potential confounding factors. The primary focus of our evaluation was to assess the impact of RT on progression-free survival (PFS) and overall survival (OS).
RESULTS:
After IPTW analysis, 49 patients received durvalumab plus platinum-etoposide (EP) chemotherapy followed by RT (Durva + EP + RT) and 72 patients received immunochemotherapy (Durva + EP). The median OS was 17.2 months vs . 12.3 months (hazard ratio [HR]: 0.38, 95% confidence interval [CI]: 0.17-0.85, P = 0.020), and the median PFS was 8.9 months vs . 5.9 months (HR: 0.56, 95% CI: 0.32-0.97, P = 0.030) in Durva + EP + RT and Durva + EP groups, respectively. Thoracic radiation therapy (TRT) resulted in longer OS (17.2 months vs . 14.7 months) and PFS (9.1 months vs . 7.2 months) compared to RT directed to other metastatic sites. Among patients with oligo-metastasis, RT also showed significant benefits, with a median OS of 17.4 months vs . 13.7 months and median PFS of 9.8 months vs . 5.9 months compared to no RT. Continuous durvalumab treatment beyond progression (TBP) prolonged OS compared to patients without TBP, in both the Durva + EP + RT (NA vs . 15.8 months, HR: 0.48, 95% CI: 0.14-1.63, P = 0.238) and Durva + EP groups (12.3 months vs . 4.3 months, HR: 0.29, 95% CI: 0.10-0.81, P = 0.018). Grade 3 or 4 adverse events occurred in 13 (26.5%) and 13 (18.1%) patients, respectively, in the two groups; pneumonitis was mostly low-grade.
CONCLUSION
Addition of RT after first-line immunochemotherapy significantly improved survival outcomes with manageable toxicity in ES-SCLC.
Humans
;
Small Cell Lung Carcinoma/therapy*
;
Retrospective Studies
;
Male
;
Female
;
Middle Aged
;
Lung Neoplasms/therapy*
;
Aged
;
Antibodies, Monoclonal/therapeutic use*
;
Adult
;
Immunotherapy/methods*
;
Aged, 80 and over
2.Machine learning-based method for interpreting the guidelines of the diagnosis and treatment of COVID-19.
Xiaorong PU ; Kecheng CHEN ; Junchi LIU ; Jin WEN ; Shangwei ZHNENG ; Honghao LI
Journal of Biomedical Engineering 2020;37(3):365-372
The outbreak of pneumonia caused by novel coronavirus (COVID-19) at the end of 2019 was a major public health emergency in human history. In a short period of time, Chinese medical workers have experienced the gradual understanding, evidence accumulation and clinical practice of the unknown virus. So far, National Health Commission of the People's Republic of China has issued seven trial versions of the "Guidelines for the Diagnosis and Treatment of COVID-19". However, it is difficult for clinicians and laymen to quickly and accurately distinguish the similarities and differences among the different versions and locate the key points of the new version. This paper reports a computer-aided intelligent analysis method based on machine learning, which can automatically analyze the similarities and differences of different treatment plans, present the focus of the new version to doctors, reduce the difficulty in interpreting the "diagnosis and treatment plan" for the professional, and help the general public better understand the professional knowledge of medicine. Experimental results show that this method can achieve the topic prediction and matching of the new version of the program text through unsupervised learning of the previous versions of the program topic with an accuracy of 100%. It enables the computer interpretation of "diagnosis and treatment plan" automatically and intelligently.
Betacoronavirus
;
China
;
Coronavirus Infections
;
diagnosis
;
therapy
;
Humans
;
Machine Learning
;
Pandemics
;
Pneumonia, Viral
;
diagnosis
;
therapy
;
Practice Guidelines as Topic
3.Systemic delivery of C Ⅱ TA siRNA reduces disease severity in collagen-induced arthritis
Danping PU ; Xiaoying WANG ; Jie ZHANG ; Yiqing ZHU ; Yingqing HU ; Xiaorong ZHOU
Chinese Journal of Microbiology and Immunology 2012;32(4):302-308
Objective To examine the therapeutic effect of C Ⅱ TA inhibition in collagen-induced arthritis(CIA),using a delivery system tailored to target C ⅡTA gene by small interfering RNA (siRNA).Methods Mice with collagen-induced arthritis were injected intravenously with C Ⅱ TA siRNA.The clinical score was monitored for up to 4 weeks after treatment.The severity of inflammation of mouse joint was evaluated by histological examination.Real-time PCR was used to determine the cytokine mRNA expression.Cytokine production was measured by ELISA from serum.T cell proliferation was examined by MTT method.Results IFN-γ and IL-17 were elevated in CIA mice,but were iuhibited significantly by C Ⅱ TA siRNA either prevention or intervention of autoimmune arthritis.Collagen specific T cell proliferation was significantly suppressed.Increased level of IL-4 by T cells was observed in C Ⅱ TA siRNA treated group compared with that of control group.Conclusion Our findings indicate that systemic RNAi-mediated C Ⅱ TA gene silencing is effective in the treatment of CIA and regulateds the balance of Th1/Th2 differentiation.
4.Development and clinical trial of fluorescence real time PCR to detect rubella virus.
Journal of Biomedical Engineering 2007;24(6):1352-1356
To establish a novel rapid, convenient, sensitive and specific method applicable to quantitative analysis of the rubella virus extensively, RV total RNA was extracted with Trizol. The envelope glycoprotein E1 gene was amplified from rubella virus by PCR, and the PCR products were cloned into the pMD18-T cloning vector and transfected into DH5alpha. After Amp selection and analysis of restriction enzyme, the clones carrying the E1 gene were identified. After quantitation and serial dilution, the quantitative analysis of E1 gene was made by real-time PCR with the use of FAM as indicator. Standard curve of the real-time PCR was plotted with starting cDNA concentration versus threshold cycle. Then the new method was used to measure 50 cases with suspectable RV infection. The results were compared with those obtained by ELISA assay. TaqMan(r)MGB real-time PCR could help evaluate the level of virus reliably. The correlation coefficient of the standard curve is 0.998, and the linear range of the system is from 10(3) copies/microl to 10(9) copies/microl in clinical samples. The CV value is 0.94% in batch assay and 3.36% in day to day assay. The new method is more sensitive and specific than ELISA assay. For its simplicity, sensitivity, specificity and digitized results, the real-time PCR for quantification of RV cDNA in clinical samples is available.
DNA, Viral
;
analysis
;
Fluorescence
;
Humans
;
Real-Time Polymerase Chain Reaction
;
methods
;
Rubella virus
;
isolation & purification
;
Sensitivity and Specificity
5.Induction of rat cerebellar granular neuron apoptosis by 1-methyl-4-phenyl pyridinium cation
Xiaoping PU ; Xiaorong LI ; Huinong LI ; Changling LI ;
Chinese Traditional and Herbal Drugs 1994;0(08):-
Object To establish a rat cerebellar granular neuron (CGN) apoptosis model by 1 methy 4 phenyl pyridinium cation (MPP +) Methods Rat CGN were treated with MPP + and the resulting cell morphology examined by methyl green pyronine staining, agarose gel electrophorsis of DNA and flow cytometry Results MPP + at the concentration of 50 ? mol/L can induce CGNs apoptosis of the established model Conclusion The CGNs apoptosis model induced by MPP + can be used for the study on regulatory mechanism of cell apoptosis and the screening of antiparkinsonian drugs

Result Analysis
Print
Save
E-mail